麻豆原创 Analysis and Insights: Global Drug Discovery Technologies 麻豆原创
The global Drug Discovery Technologies market is projected to grow from US$ 51640 million in 2023 to US$ 76370 million by 2029, at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period.
The US & Canada market for Drug Discovery Technologies is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for Drug Discovery Technologies is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for Drug Discovery Technologies is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key companies of Drug Discovery Technologies include Agilent, GE Healthcare, Albany Molecular Research Inc., Affymetrix, Bayer Healthcare, Novartis and AstraZeneca, etc. in 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for Drug Discovery Technologies market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Drug Discovery Technologies, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Drug Discovery Technologies, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Drug Discovery Technologies revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Drug Discovery Technologies market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Drug Discovery Technologies revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Agilent, GE Healthcare, Albany Molecular Research Inc., Affymetrix, Bayer Healthcare, Novartis and AstraZeneca, etc.
By Company
Agilent
GE Healthcare
Albany Molecular Research Inc.
Affymetrix
Bayer Healthcare
Novartis
AstraZeneca
Segment by Type
Biochips
High throughput screening
Pharmacogenomics
Genomics
Bioanalytical instruments
Bioinformatics
Nanotechnology
Others
Segment by Application
Pharmaceutical Companies
Research Institutes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Drug Discovery Technologies in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drug Discovery Technologies companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drug Discovery Technologies revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Drug Discovery Technologies 麻豆原创 Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Biochips
1.2.3 High throughput screening
1.2.4 Pharmacogenomics
1.2.5 Genomics
1.2.6 Bioanalytical instruments
1.2.7 Bioinformatics
1.2.8 Nanotechnology
1.2.9 Others
1.3 麻豆原创 by Application
1.3.1 Global Drug Discovery Technologies 麻豆原创 Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical Companies
1.3.3 Research Institutes
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drug Discovery Technologies 麻豆原创 Perspective (2018-2029)
2.2 Global Drug Discovery Technologies Growth Trends by Region
2.2.1 Drug Discovery Technologies 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Drug Discovery Technologies Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Drug Discovery Technologies Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Drug Discovery Technologies 麻豆原创 Dynamics
2.3.1 Drug Discovery Technologies Industry Trends
2.3.2 Drug Discovery Technologies 麻豆原创 Drivers
2.3.3 Drug Discovery Technologies 麻豆原创 Challenges
2.3.4 Drug Discovery Technologies 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Drug Discovery Technologies by Players
3.1.1 Global Drug Discovery Technologies Revenue by Players (2018-2023)
3.1.2 Global Drug Discovery Technologies Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Drug Discovery Technologies 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Drug Discovery Technologies, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Drug Discovery Technologies 麻豆原创 Concentration Ratio
3.4.1 Global Drug Discovery Technologies 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drug Discovery Technologies Revenue in 2022
3.5 Global Key Players of Drug Discovery Technologies Head office and Area Served
3.6 Global Key Players of Drug Discovery Technologies, Product and Application
3.7 Global Key Players of Drug Discovery Technologies, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Drug Discovery Technologies Breakdown Data by Type
4.1 Global Drug Discovery Technologies Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Drug Discovery Technologies Forecasted 麻豆原创 Size by Type (2024-2029)
5 Drug Discovery Technologies Breakdown Data by Application
5.1 Global Drug Discovery Technologies Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Drug Discovery Technologies Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Drug Discovery Technologies 麻豆原创 Size (2018-2029)
6.2 North America Drug Discovery Technologies 麻豆原创 Size by Type
6.2.1 North America Drug Discovery Technologies 麻豆原创 Size by Type (2018-2023)
6.2.2 North America Drug Discovery Technologies 麻豆原创 Size by Type (2024-2029)
6.2.3 North America Drug Discovery Technologies 麻豆原创 Share by Type (2018-2029)
6.3 North America Drug Discovery Technologies 麻豆原创 Size by Application
6.3.1 North America Drug Discovery Technologies 麻豆原创 Size by Application (2018-2023)
6.3.2 North America Drug Discovery Technologies 麻豆原创 Size by Application (2024-2029)
6.3.3 North America Drug Discovery Technologies 麻豆原创 Share by Application (2018-2029)
6.4 North America Drug Discovery Technologies 麻豆原创 Size by Country
6.4.1 North America Drug Discovery Technologies 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Drug Discovery Technologies 麻豆原创 Size by Country (2018-2023)
6.4.3 North America Drug Discovery Technologies 麻豆原创 Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Drug Discovery Technologies 麻豆原创 Size (2018-2029)
7.2 Europe Drug Discovery Technologies 麻豆原创 Size by Type
7.2.1 Europe Drug Discovery Technologies 麻豆原创 Size by Type (2018-2023)
7.2.2 Europe Drug Discovery Technologies 麻豆原创 Size by Type (2024-2029)
7.2.3 Europe Drug Discovery Technologies 麻豆原创 Share by Type (2018-2029)
7.3 Europe Drug Discovery Technologies 麻豆原创 Size by Application
7.3.1 Europe Drug Discovery Technologies 麻豆原创 Size by Application (2018-2023)
7.3.2 Europe Drug Discovery Technologies 麻豆原创 Size by Application (2024-2029)
7.3.3 Europe Drug Discovery Technologies 麻豆原创 Share by Application (2018-2029)
7.4 Europe Drug Discovery Technologies 麻豆原创 Size by Country
7.4.1 Europe Drug Discovery Technologies 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Drug Discovery Technologies 麻豆原创 Size by Country (2018-2023)
7.4.3 Europe Drug Discovery Technologies 麻豆原创 Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Drug Discovery Technologies 麻豆原创 Size (2018-2029)
8.2 China Drug Discovery Technologies 麻豆原创 Size by Type
8.2.1 China Drug Discovery Technologies 麻豆原创 Size by Type (2018-2023)
8.2.2 China Drug Discovery Technologies 麻豆原创 Size by Type (2024-2029)
8.2.3 China Drug Discovery Technologies 麻豆原创 Share by Type (2018-2029)
8.3 China Drug Discovery Technologies 麻豆原创 Size by Application
8.3.1 China Drug Discovery Technologies 麻豆原创 Size by Application (2018-2023)
8.3.2 China Drug Discovery Technologies 麻豆原创 Size by Application (2024-2029)
8.3.3 China Drug Discovery Technologies 麻豆原创 Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Drug Discovery Technologies 麻豆原创 Size (2018-2029)
9.2 Asia Drug Discovery Technologies 麻豆原创 Size by Type
9.2.1 Asia Drug Discovery Technologies 麻豆原创 Size by Type (2018-2023)
9.2.2 Asia Drug Discovery Technologies 麻豆原创 Size by Type (2024-2029)
9.2.3 Asia Drug Discovery Technologies 麻豆原创 Share by Type (2018-2029)
9.3 Asia Drug Discovery Technologies 麻豆原创 Size by Application
9.3.1 Asia Drug Discovery Technologies 麻豆原创 Size by Application (2018-2023)
9.3.2 Asia Drug Discovery Technologies 麻豆原创 Size by Application (2024-2029)
9.3.3 Asia Drug Discovery Technologies 麻豆原创 Share by Application (2018-2029)
9.4 Asia Drug Discovery Technologies 麻豆原创 Size by Region
9.4.1 Asia Drug Discovery Technologies 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Drug Discovery Technologies 麻豆原创 Size by Region (2018-2023)
9.4.3 Asia Drug Discovery Technologies 麻豆原创 Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Drug Discovery Technologies 麻豆原创 Size (2018-2029)
10.2 Middle East, Africa, and Latin America Drug Discovery Technologies 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Drug Discovery Technologies 麻豆原创 Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Drug Discovery Technologies 麻豆原创 Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Drug Discovery Technologies 麻豆原创 Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Drug Discovery Technologies 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Drug Discovery Technologies 麻豆原创 Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Drug Discovery Technologies 麻豆原创 Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Drug Discovery Technologies 麻豆原创 Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Drug Discovery Technologies 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Drug Discovery Technologies 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Drug Discovery Technologies 麻豆原创 Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Drug Discovery Technologies 麻豆原创 Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Agilent
11.1.1 Agilent Company Details
11.1.2 Agilent Business Overview
11.1.3 Agilent Drug Discovery Technologies Introduction
11.1.4 Agilent Revenue in Drug Discovery Technologies Business (2018-2023)
11.1.5 Agilent Recent Developments
11.2 GE Healthcare
11.2.1 GE Healthcare Company Details
11.2.2 GE Healthcare Business Overview
11.2.3 GE Healthcare Drug Discovery Technologies Introduction
11.2.4 GE Healthcare Revenue in Drug Discovery Technologies Business (2018-2023)
11.2.5 GE Healthcare Recent Developments
11.3 Albany Molecular Research Inc.
11.3.1 Albany Molecular Research Inc. Company Details
11.3.2 Albany Molecular Research Inc. Business Overview
11.3.3 Albany Molecular Research Inc. Drug Discovery Technologies Introduction
11.3.4 Albany Molecular Research Inc. Revenue in Drug Discovery Technologies Business (2018-2023)
11.3.5 Albany Molecular Research Inc. Recent Developments
11.4 Affymetrix
11.4.1 Affymetrix Company Details
11.4.2 Affymetrix Business Overview
11.4.3 Affymetrix Drug Discovery Technologies Introduction
11.4.4 Affymetrix Revenue in Drug Discovery Technologies Business (2018-2023)
11.4.5 Affymetrix Recent Developments
11.5 Bayer Healthcare
11.5.1 Bayer Healthcare Company Details
11.5.2 Bayer Healthcare Business Overview
11.5.3 Bayer Healthcare Drug Discovery Technologies Introduction
11.5.4 Bayer Healthcare Revenue in Drug Discovery Technologies Business (2018-2023)
11.5.5 Bayer Healthcare Recent Developments
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Drug Discovery Technologies Introduction
11.6.4 Novartis Revenue in Drug Discovery Technologies Business (2018-2023)
11.6.5 Novartis Recent Developments
11.7 AstraZeneca
11.7.1 AstraZeneca Company Details
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Drug Discovery Technologies Introduction
11.7.4 AstraZeneca Revenue in Drug Discovery Technologies Business (2018-2023)
11.7.5 AstraZeneca Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Agilent
GE Healthcare
Albany Molecular Research Inc.
Affymetrix
Bayer Healthcare
Novartis
AstraZeneca
听
听
*If Applicable.
